$0.23
6.37% yesterday
Nasdaq, Aug 07, 10:02 pm CET
ISIN
US29350E1047
Symbol
RENB

Renovaro Stock price

$0.23
-0.07 24.11% 1M
-0.48 67.90% 6M
-0.61 73.07% YTD
-0.41 64.45% 1Y
-2.51 91.76% 3Y
-4.33 95.05% 5Y
-4.28 95.00% 10Y
-5.78 96.25% 20Y
Nasdaq, Closing price Thu, Aug 07 2025
-0.02 6.37%
ISIN
US29350E1047
Symbol
RENB
Industry

Key metrics

Basic
Market capitalization
$55.5m
Enterprise Value
$59.8m
Net debt
$4.4m
Cash
$1.6m
Shares outstanding
162.4m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.6
Financial Health
Equity Ratio
80.9%
Return on Equity
-61.4%
ROCE
-21.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-19.3m | -
EBIT
$-19.4m | -
Net Income
$-67.3m | -
Free Cash Flow
$-8.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
19.5% | -
EBIT
19.4% | -
Net Income
23.5% | -
Free Cash Flow
21.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.1
Short interest
0.7%
Employees
25
Rev per Employee
$0.0
Show more

Is Renovaro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Financial data from Renovaro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
11% 11%
-
- Research and Development Expense 0.89 0.89
73% 73%
-
-19 -19
20% 20%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -19 -19
19% 19%
-
Net Profit -67 -67
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Renovaro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Renovaro Stock News

Neutral
Accesswire
10 days ago
Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificia...
Neutral
Accesswire
21 days ago
Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a leading journal in the field of immunology. Th...
Neutral
Accesswire
30 days ago
LOS ANGELES, CA / ACCESS Newswire / July 9, 2025 / Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company, today announced that senior debt holders have agreed to convert an aggregate of approximately $9.7 million of outstanding senior debt into convertible debt which they have elected to convert into equity. Under the terms of the agreement, the Company will issue an aggregate of...
More Renovaro News

Company Profile

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Head office United States
CEO David Weinstein
Employees 25
Founded 2011
Website renovarobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today